Abstract
The acute phase of ischemic stroke (IS) is characterized by rapid escalation of neuroinflammation, concomitant with disruption of tight junction proteins and increased blood-brain barrier (BBB) permeability. These pathological alterations facilitate the influx of circulating immune components and inflammatory signals into the injured brain regions, thereby exacerbating neuronal death and neurological dysfunction. Ginkgo biloba leaves have been shown to possess well-established therapeutic properties against IS. Ginkgo biloba leaf-derived exosome-like nanoparticles (GELNs) preserve the bioactive constituents of their source material and exhibit favorable biocompatibility, positioning them as a promising therapeutic modality for IS. However, their low brain-targeting capability limits their clinical translation. To overcome this limitation, we used the microthrombus-targeting peptide CREKA to surface-modify GELNs, successfully constructing CREKA-GELNs. Following tail vein injection, CREKA-GELNs can specifically target cerebral microthrombi and pass through the damaged BBB into the brain parenchyma to exert anti-inflammatory and neuroprotective effects. In addition, it can promote the structural repair of the damaged BBB; notably, once the BBB is significantly repaired, the accumulation of CREKA-GELNs in the brain decreases accordingly. Collectively, this nanoparticle delivery platform offers a safe, effective and controllable strategy for the treatment of IS.
京公网安备11010802044758号
Comments on this article